Clinical Trials Sponsored by Spherix Incorporated

Total 1227 results

Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-668

Alpha-1 Antitrypsin Deficiency

United States
Lexington Health Incorporated

Active, not recruiting

Transoral Fundoplication Prior to Sleeve Gastrectomy Versus RNY Gastric Bypass on GERD Symptoms in Bariatric Patients

Gastroesophageal Reflux Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-634

Alpha 1-Antitrypsin Deficiency

United States
Bausch & Lomb Incorporated

Completed

Effects of NOV03 on the Tear Film

Dry Eye Disease (DED)

United States
Bausch & Lomb Incorporated

Completed

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Dry Eye Disease (DED)

United States
Bausch & Lomb Incorporated

Withdrawn

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Ocular Hypertension

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Bausch & Lomb Incorporated

Completed

1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses

Refractive Ametropia

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Focal Segmental Glomerulosclerosis (FSGS)

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

France, Spain, Belgium, Netherlands, Australia, Italy, Czechia
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Campbell University, Incorporated

Completed

Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics (SAMI)

Diabetes

United States
Bausch & Lomb Incorporated

Completed

A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

Contact Lens Wear

United States
Cook Group Incorporated

Completed

Zenith® TXD Post-market Surveillance in Japan

Aortic Dissection

Japan
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Acute Pain

United Kingdom
Bausch & Lomb Incorporated

Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Glaucoma | Open Angle or Ocular Hypertension

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Bausch & Lomb Incorporated

Completed

A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses

Contact Lens Wear

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

APOL1-mediated Kidney Disease

United States
Torax Medical Incorporated

Completed

LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy (RELIEF)

Gastroesophageal Reflux Disease | GERD

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
Bausch & Lomb Incorporated

Completed

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

Dry Eye Disease

United States
Bausch & Lomb Incorporated

Completed

1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Presbyopia

Presbyopia

United States
Bausch & Lomb Incorporated

Completed

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Dry Eye Disease (DED)

United States
Campbell University, Incorporated

Completed

The Effects of Lower Extremity Blood Flow Restriction Training on Power, and Muscle Size.

Healthy

United States
Bausch & Lomb Incorporated

Completed

A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution

Contact Lens Wear

United States
Vertex Pharmaceuticals Incorporated

Terminated

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Alpha 1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic Fibrosis

United States, Belgium, Netherlands, Australia, Germany, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Small Fiber Neuropathy

United States, Netherlands, Germany, Italy
Castle Biosciences Incorporated

Terminated

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes (EXPAND)

Cutaneous Melanoma

United States
Ideal Implant Incorporated

Completed

Core Study of the Safety and Effectiveness of IDEAL IMPLANT(R) Saline-filled Breast Implants

Breast Implants

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Cook Biotech Incorporated

Completed

Treatment of Wounds Using Oasis® ECM

Non-healing Wound

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Approved for marketing

ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation

Cystic Fibrosis
Torax Medical Incorporated

Completed

Observational Study of Anti-Reflux Surgery

Gastroesophageal Reflux | Gastro Esophageal Reflux | GERD

Italy, Austria, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Sound Pharmaceuticals, Incorporated

Completed

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Meniere's Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Bausch & Lomb Incorporated

Completed

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Age-Related Macular Degeneration | Diabetic Macular Edema | Retinal Vein Occlusion

United States
Bausch & Lomb Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact Lens

Contact Lens Wear

United States
Cook Group Incorporated

Completed

Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions

Peripheral Arterial Disease | Critical Limb Ischemia

United States, Germany, Italy
Bausch & Lomb Incorporated

Completed

A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact Lenses

Myopia

United States

Clinical Trials Sponsored by Spherix Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations